{
  "id": 19704277,
  "title": "AHA: Pelacarsen cuts lipoprotein(a) levels but does not lower risk for major adverse cardiovascular events",
  "url": "https://urgent.news/2026/11/12/aha-pelacarsen-cuts-lipoprotein-a-levels-but-does-not-lower-risk-for",
  "topic": "science",
  "section": "Science",
  "published": "2026-11-12T20:00:06.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-11-aha-pelacarsen-lipoproteina-major-adverse.html"
  },
  "original_language": "en",
  "account": null,
  "summary": "For adults with preexisting cardiovascular disease, pelacarsen, an antisense oligonucleotide administered monthly, lowers lipoprotein(a) levels but does not reduce the occurrence of major adverse cardiovascular events, according to a study published online Nov. 7 in the New England Journal of Medicine to coincide with the American Heart Association Scientific Sessions 2026, held from Nov. 6 to 9…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}